Take ibuprofen or equivalent NSAIDs for menstrual pain rather than enduring it; if pain disrupts work or school or persists despite three months of medication, seek gynecological evaluation

For primary menstrual cramps (dysmenorrhea), over-the-counter NSAIDs like ibuprofen increase the proportion of women achieving moderate-to-excellent pain relief from under 20% to roughly 50%. They are significantly more effective than acetaminophen, with slightly more mild stomach side effects. If pain is severe enough to miss work or school, causes deep pelvic pain during intercourse, or fails to respond after 3 months of medication, consult a gynecologist to evaluate for endometriosis, which takes an average of 6.7 years to be formally diagnosed.

A box of over-the-counter ibuprofen costs a few dollars, taken only during symptomatic days. If clinical evaluation is required, outpatient consultation and pelvic ultrasonography take half a day and standard copay costs.

A Cochrane systematic review pooled 80 randomized controlled trials comprising 5,820 women with primary dysmenorrhea (menstrual pain without identifiable pelvic pathology). Compared to placebo, nonsteroidal anti-inflammatory drugs (NSAIDs) were substantially more effective for pain relief (OR 4.37, 95% CI 3.76–5.09): while only 18% of women on placebo achieved moderate to excellent pain relief, 45% to 53% on NSAIDs achieved relief. Adverse effects were moderately higher with NSAIDs (OR 1.29, 95% CI 1.11–1.51), affecting 11% to 14% of NSAID users versus 10% on placebo, predominantly mild gastrointestinal discomfort (OR 1.58) and transient nervous system effects (OR 2.74). Compared directly with acetaminophen (paracetamol), NSAIDs demonstrated superior pain reduction (OR 1.89, 95% CI 1.05–3.43 across 3 trials), with no clear efficacy differences among specific NSAID molecules. Updated 2024 National Institute for Health and Care Excellence (NICE) guidelines advise suspecting endometriosis in women (including adolescents aged 17 and under) who present with persistent pelvic pain, period pain that impairs daily activities and quality of life, deep pain during or after sexual intercourse, painful bowel movements or urination during menstruation, or unexplained subfertility associated with any of these symptoms. NICE recommends an initial 3-month trial of first-line analgesics (acetaminophen or NSAIDs); if symptom control remains inadequate, prompt specialist gynecological referral is recommended. Crucially, a completely normal pelvic examination and normal ultrasound do not exclude endometriosis. In a prospective multicenter study across 16 hospitals in 10 countries involving 1,418 women undergoing diagnostic laparoscopy, the diagnostic delay between initial symptom onset and surgically confirmed endometriosis averaged 6.7 years, primarily driven by delayed primary care recognition. Women with confirmed endometriosis reported an average weekly loss of 10.8 productive hours, predominantly through impaired on-the-job performance (presenteeism). A nationwide Dutch survey of 32,748 women aged 15–45 found that 13.8% had taken formal sick leave due to menstrual symptoms (mean 1.3 days per year), while 80.7% reported presenteeism, culminating in an average loss of 8.9 productive workdays per woman annually.

Individuals aged 60 and older, those with past gastrointestinal bleeding, or those currently taking anticoagulants or systemic corticosteroids must consult a physician prior to using NSAIDs (detailed in Chapter 34, Rule 3). FDA drug labeling notes that ibuprofen may cause severe allergic reactions, particularly in individuals with aspirin sensitivity; those with active asthma should seek medical advice beforehand. Never self-administer NSAIDs after 20 weeks of gestation due to fetal renal risks (detailed in Chapter 34, Rule 5). For individuals who cannot tolerate NSAIDs, acetaminophen is a suitable alternative (observe daily maximum dosage limits in Chapter 34, Rule 1). Pain medication for dysmenorrhea is taken acutely during the first few days of menstruation; it does not reach the monthly medication-overuse headache threshold (15 days per month) described in Chapter 34, Rule 9. Grade A reflects high-volume randomized trials. Benefit magnitude is categorized as Moderate based on the symptom reduction and restored daily functionality. Primary beneficiary is yourself.

Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M (2015). Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews, (7):CD001751. https://doi.org/10.1002/14651858.CD001751.pub3；National Institute for Health and Care Excellence (2017, updated 2024). Endometriosis: diagnosis and management (NG73), recommendations 1.3.1, 1.4.2, 1.4.3, 1.5.4. https://www.nice.org.uk/guidance/ng73/chapter/Recommendations；Nnoaham KE, Hummelshoj L, Webster P, et al.; World Endometriosis Research Foundation Global Study of Women's Health consortium (2011). Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertility and Sterility, 96(2):366-373.e8. https://doi.org/10.1016/j.fertnstert.2011.05.090；Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE (2019). Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open, 9(6):e026186. https://doi.org/10.1136/bmjopen-2018-026186；Haleon (2026). Advil (ibuprofen capsule, liquid filled), OTC drug label: Warnings. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f01c10a-9434-91a4-2ee4-352315a6b610